Randomization Does Not Solve Sample Identity

Overview

Yes — even a rigorously randomized trial can leave basic questions about what was actually given to participants unanswered. Randomization protects against allocation bias and helps estimate causal effects between trial arms. It does not, by itself, establish what chemical entity, formulation, contaminants, stability profile, or batch-specific characteristics were present in the materials participants received. Answering those product-composition questions requires separate analytical and manufacturing evidence.

Why this matters: if you want to read a trial and understand whether the investigational or comparator substance was what it was claimed to be, look beyond the randomization statement and ask for laboratory and manufacturing documentation.

How randomization and sample identity address different problems

These two domains intersect in a complete evidence package for interpreting trial results, but they are distinct tasks. The former is a trial-design feature; the latter depends on quality control, analytical chemistry, and documentation from manufacturing and testing.

Five types of evidence needed to establish sample identity Below are the common classes of evidence readers should look for when trial claims about product composition need verification. A concise table follows to clarify which evidence addresses which question.

1) Identity testing: methods and results

2) Assay and quantitative content

3) Impurities and contaminants

4) Stability and storage conditions

5) Batch traceability and chain-of-custody

Table: Evidence type versus the question it answers | Evidence type | Establishes | |---|---| | Identity testing | That the stated chemical entity was present | | Assay results + uncertainty | How much active ingredient was present | | Impurity/contaminant testing | Whether unwanted substances were present above limits | | Stability data/storage records | Whether composition persisted over time/conditions | | Batch linkage/chain-of-custody | That the tested sample is the same lot used in the trial |

What sources or documents typically contain this evidence

How to read a trial with sample-identity scrutiny — a practical approach 1. Look for explicit CMC or quality sections in the trial dossier or publication. Do they report analytical methods, certificates of analysis (CoAs), stability statements, and batch numbers? If so, are CoAs linked to the lots used in the clinical phase? 2. Check whether identity testing methods and assay results are described with limits of detection, calibration against standards, and uncertainty estimates. Absence of these details leaves composition questions open. 3. Search for impurity and contaminant testing results and their acceptance criteria. If none are reported, ask whether contamination testing was performed and how results were handled. 4. Verify whether sample chain-of-custody or batch-traceability statements connect analytical tests to the clinical supplies. Analyses performed on different lots or unlabelled retained samples cannot prove the clinical material’s identity without that linkage. 5. When regulators or manufacturers are cited, note the scope of their documentation. Regulatory guidance describes expectations but does not substitute for batch-specific evidence submitted for a particular study .

Limits of what can be concluded from available documents

This is research-source literacy, not medical advice: these steps help you evaluate the evidence about what a trial’s participants were given. They do not provide dosing, treatment, or clinical recommendations and do not infer individual outcomes from incomplete or preclinical evidence.

Cited sources: Health Canada guidance on CMC expectations for drug submissions ; guide on uncertainty in sampling and measurements ; editorial research resource .

• Randomization controls assignment. Its purpose is to make groups comparable on measured and unmeasured prognostic factors so differences in outcomes can be attributed to assigned interventions rather than selection bias or confounding.
• Sample identity is a manufacturing and analytical problem. It concerns what the material is (identity), how much of the stated active ingredient is present (assay), whether impurities or contaminants exist (purity/impurities), whether the product remains stable under storage and use conditions (stability), and whether the specific clinical supplies link to a particular production batch (batch linkage/chain-of-custody).
• Tests such as spectral methods, chromatography with reference standards, or specific chemical assays can show whether the labeled active substance is present. A trial report that merely names a compound without reporting the analytical methods, limits of detection, or comparison to an authenticated reference leaves identity unresolved.
• Stating a target assay (e.g., “contains X mg per vial”) is not the same as providing measured assay results and their uncertainty. Assay data should include analytical methods, calibration against standards, and uncertainty estimates. Without assay reporting, there is no independent basis to accept that dose-level or concentration assertions reflect the actual supplied material.
• Contaminant testing (microbiological, chemical, heavy metals, solvents, etc.) requires explicit methods, specification limits, and measured results. The presence or absence of specified impurities, and whether they fall within acceptable thresholds, cannot be inferred from randomization alone.
• Stability studies or at least documented storage conditions and expiry information affect whether a product remained within specification during the trial. A batch that met assay at manufacture but degraded in storage could differ materially from what participants received.
• To relate analytical test results to the actual clinical supplies, documentation must link specific analytical certificates to the same lot numbers, containers, or labels used in the trial. Without that batch linkage, lab results from a manufacturer or external lab cannot definitively prove the clinical material’s composition.
• Regulatory submissions and quality guidance describe the expectations for evidence supporting product quality. For example, Health Canada’s guidance on quality for drug submissions explains what chemistry, manufacturing and controls (CMC) documentation typically covers for new and abbreviated drug submissions, including identity, assay, impurities, and stability data for batches used in studies .
• Practical analytical guidance clarifies uncertainty around sampling and testing. Guides on sampling uncertainty and representative sampling explain that analytical results have measurement uncertainty and that sampling strategy matters for linking a test result to a larger lot or production run .
• If a trial publication only states that supplies were “from GMP manufacture” or “quality assured,” these phrases alone are not detailed evidence. They indicate a compliance claim but do not show the specific analyses, results, or batch linkage needed to confirm what participants received.
• Where analytical or manufacturing data are incomplete or absent, the unresolved question is precisely whether the supplied material matched the stated composition, assay, impurity profile, and stability. That gap changes how confidently one can attribute observed effects to a particular chemical composition.